What Researchers Did
Researchers conducted a Phase II trial on 61 bladder carcinoma patients treated with radiotherapy plus carbogen (with or without nicotinamide) and compared outcomes to two historical trials using hyperbaric oxygen or misonidazole.
What They Found
The carbogen group, with or without nicotinamide, showed significantly better local control (P = 0.00001), progression-free survival (P = 0.001), and overall survival (P = 0.04) compared to historical groups treated with hyperbaric oxygen or misonidazole. No significant difference was observed between the hyperbaric oxygen and misonidazole trials themselves.
What This Means for Canadian Patients
This study suggests that adding carbogen, potentially with nicotinamide, to radical radiotherapy could improve outcomes for Canadian patients with locally advanced bladder carcinoma. These findings may inform future treatment strategies aimed at enhancing local control and survival for this patient population.
Canadian Relevance
This study has no direct Canadian connection as it was conducted outside of Canada.
Study Limitations
A limitation is that the observed advantage for the carbogen group might be partly attributable to evolving radiotherapy practices over the duration of the three comparative studies.